Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueNo recent work listed

Céline Loncle

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5000793990. Sources: OpenAlex.

Their work

Papers
17 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
57
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: 5 papers · 2016: 3 papers · 2017: 3 papers · 2018: none · 2019: none · 2020: none · 2021: 1 paper

Papers 17

  1. Dendrimeric nanosystem consistently circumvents heterogeneous drug response and resistance in pancreatic cancer. Co-author DOI 10.1002/exp.20210003↗
  2. Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts. Co-author DOI 10.1016/j.celrep.2017.11.003↗
  3. BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC). First author DOI 10.1080/2162402x.2017.1372080↗
  4. Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individua… Co-author DOI 10.15252/emmm.201606975↗
  5. The pancreatitis-associated protein VMP1, a key regulator of inducible autophagy, promotes Kras(G12D)-mediated pancreatic cancer initiation. Co-author DOI 10.1038/cddis.2016.202↗
  6. Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness. Co-author DOI 10.1172/jci87734↗
  7. A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT. Co-author DOI 10.18632/oncotarget.10776↗
  8. Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ajpath.2014.11.029↗
  9. Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. Co-author DOI 10.1073/pnas.1421601112↗
  10. IL17 Functions through the Novel REG3β-JAK2-STAT3 Inflammatory Pathway to Promote the Transition from Chronic Pancreatitis to Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-15-0896↗
  11. A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor. First author DOI 10.18632/oncotarget.2685↗
  12. Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.3510↗
  13. IER3 supports KRASG12D-dependent pancreatic cancer development by sustaining ERK1/2 phosphorylation. Co-author DOI 10.1172/jci76037↗
  14. Further characterization of HDAC and SIRT gene expression patterns in pancreatic cancer and their relation to disease outcome. Co-author DOI 10.1371/journal.pone.0108520↗
  15. Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Co-author DOI 10.1073/pnas.1219555110↗
  16. Homotypic cell cannibalism, a cell-death process regulated by the nuclear protein 1, opposes to metastasis in pancreatic cancer. Co-author DOI 10.1002/emmm.201201255↗
  17. p8 expression controls pancreatic cancer cell migration, invasion, adhesion, and tumorigenesis. Co-author DOI 10.1002/jcp.22702↗

Closest collaborators

The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Juan Iovanna · 17 shared papers, 2011–2021 · strength 0.76
  2. Nelson Dusetti · 11 shared papers, 2013–2021 · strength 0.55
  3. Odile Gayet · 8 shared papers, 2015–2021 · strength 0.40
  4. Mehdi Ouaïssi · 9 shared papers, 2014–2017 · strength 0.36
  5. Véronique Secq · 8 shared papers, 2012–2017 · strength 0.33
  6. Olivıer Turrini · 8 shared papers, 2012–2017 · strength 0.31
  7. Raul A. Urrutia · 6 shared papers, 2012–2017 · strength 0.26
  8. Gwen Alyce Lomberk · 6 shared papers, 2012–2017 · strength 0.26
  9. Marine Gilabert · 6 shared papers, 2015–2017 · strength 0.25
  10. Marc F. Giovannini · 5 shared papers, 2015–2017 · strength 0.21
  11. Pauline Duconseil · 5 shared papers, 2015–2017 · strength 0.20
  12. Sophie Vasseur · 5 shared papers, 2013–2017 · strength 0.20
  13. Jean‐Luc Raoul · 4 shared papers, 2015–2017 · strength 0.17
  14. Richard Tomasini · 4 shared papers, 2013–2016 · strength 0.15
  15. María Inés Molejon · 3 shared papers, 2015–2016 · strength 0.14
  16. Benjamin Bian · 3 shared papers, 2016–2017 · strength 0.13
  17. Jean‐Robert Delpéro · 3 shared papers, 2016–2017 · strength 0.13
  18. Julie Roques · 3 shared papers, 2015–2017 · strength 0.12
  19. Anthony Gonçalvès · 3 shared papers, 2015–2017 · strength 0.12
  20. Fabienne Guillaumond · 3 shared papers, 2013–2017 · strength 0.11
  21. Xing‐Jie Liang · 1 shared paper, 2021 · strength 0.11
  22. Juan Liu · 1 shared paper, 2021 · strength 0.11
  23. Ling Peng · 1 shared paper, 2021 · strength 0.11
  24. Tewfik Hamidi · 3 shared papers, 2011–2014 · strength 0.10
  25. Rémy Nicolle · 2 shared papers, 2017 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.